title: Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis.
abstract: Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log(10) RNA levels were similar. Adjustment for covariates (CD4(+) T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log(10) HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P=.12) and respective log mean rates of change per month of -0.08 versus -0.21 (P=.08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.
authors.affiliation: Center for Clinical Trials, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. mdavidso@gci.net
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
authors.forename: Yuan-I
authors.initials: YI
authors.lastname: Min
authors.forename: Janet T
authors.initials: JT
authors.lastname: Holbrook
authors.forename: Mark
authors.initials: M
authors.lastname: Van Natta
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Quinn
authors.forename: Robert L
authors.initials: RL
authors.lastname: Murphy
authors.forename: William
authors.initials: W
authors.lastname: Welch
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jabs
authors.forename: Curtis L
authors.initials: CL
authors.lastname: Meinert
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D017726:Cytomegalovirus Retinitis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D000069585:Filgrastim; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000209:etiology / Q000517:prevention & control; D012367:RNA, Viral / Q000097:blood*; D011994:Recombinant Proteins; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim